Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Thyssen, Jacob P. ^{[2
]}

Guttman-Yassky, Emma ^{[3
]}

Bieber, Thomas ^{[4
]}

Carrascosa, Jose Manuel ^{[5
]}

Simpson, Eric ^{[6
]}

Rosmarin, David ^{[7
]}

Elmaraghy, Hany ^{[8
]}

Meskimen, Eric ^{[8
]}

Natalie, Chitra R. ^{[8
]}

Liu, Zhuqing ^{[8
]}

Xu, Chenjia ^{[8
]}

Pierce, Evangeline ^{[8
]}

Morgan-Cox, MaryAnn ^{[8
]}

Silverberg, Jonathan, I ^{[9
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR 97223 USA

[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark

[3] Icahn Sch Med Mt Sinai, New York, NY USA

[4] Univ Hosp Bonn, Bonn, Germany

[5] UAB, Germans Trias i Pujol Univ Hosp, IGTP, Barcelona, Spain

[6] Oregon Hlth & Sci Univ, Portland, OR USA

[7] Tufts Univ, Sch Med, Boston, MA USA

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷

关键词：

monotherapy; atopic dermatitis; moderate-to-severe; lebrikizumab; interleukin (IL)-13;

D O I：

10.1093/bjd/ljac140.018

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

322

引用

页数：2

共 50 条

[31] Rocatinlimab Improves Patient-Reported Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis: Results from a Double-Blind Placebo-Controlled Phase 2b Study
Gooderham, Melinda
Guttman-Yassky, Emma
Igawa, Ken
Kabashima, Kenji
Esfandiari, Ehsanollah
Rylands, Angela J.
Williams, Angela
Nixon, Annabel
Dent, Jennifer E.
Simpson, Eric
DERMATOLOGY AND THERAPY, 2024, 14 (12) : 3351 - 3366
[32] Efficacy and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: subgroup analysis of the Measure Up 1, Measure Up 2 and AD Up phase 3 clinical trials at 52 weeks
Paller, Amy S.
Mendes-Bastos, Pedro
Eichenfield, Lawrence F.
Soong, Weily
Lio, Peter
Prajapati, Vimal H.
Platt, Andrew M.
Raymundo, Eliza
Liu, John
Ladizinski, Barry
Thyssen, Jacob P.
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[33] Impact of amlitelimab (an anti-OX40 ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe atopic dermatitis
Blauvelt, Andrew
Chovatiya, Raj
Merola, Joseph F.
Weidinger, Stephan
Igawa, Ken
Zikos, Efstathios
Weber, Christine
Wang, Jennifer
Gray, Cori
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[34] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
Eric L. Simpson
Dermatology and Therapy, 2017, 7 : 243 - 248
[35] Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
Simpson, Eric L.
DERMATOLOGY AND THERAPY, 2017, 7 (02) : 243 - 248
[36] Efficacy and safety of topically applied therapeutic ammonia oxidising bacteria in adults with mild-to-moderate atopic dermatitis and moderate-to-severe pruritus: a randomised, double-blind, placebo-controlled, dose-ranging, phase 2b trial
Silverberg, Jonathan I.
Lio, Peter A.
Simpson, Eric L.
Li, Connie
Brownell, Daniel R.
Gryllos, Ioannis
Ng-Cashin, Judith
Krueger, Todd
Swaidan, Victoria R.
Bliss, Robin L.
Kim, Hyun D.
ECLINICALMEDICINE, 2023, 60
[37] Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
Guttman-Yassky, Emma
Brunner, Patrick M.
Neumann, Avidan U.
Khattri, Saakshi
Pavel, Ana B.
Malik, Kunal
Singer, Giselle K.
Baum, Danielle
Gilleaudeau, Patricia
Sullivan-Whalen, Mary
Rose, Sharon
On, Shelbi Jim
Li, Xuan
Fuentes-Duculan, Judilyn
Estrada, Yeriel
Garcet, Sandra
Traidl-Hoffmann, Claudia
Krueger, James G.
Lebwohl, Mark G.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 78 (05) : 872 - +
[38] Efficacy of dupilumab treatment in atopic hand and foot dermatitis across morphological subtypes: results from a phase 3, randomized, double-blind, placebo-controlled trial
Worm, Margitta
Simpson, Eric L.
Honari, Golara
Soong, Weily
Pinter, Andreas
Masuda, Koji
Shao, Liyang
Dubost-Brama, Ariane
Bansal, Ashish
Korotzer, Andrew
Rossi, Ana B.
BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 : II60 - II60
[39] Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
Blauvelt, Andrew
Ladizinski, Barry
Prajapati, Vimal H.
Laquer, Vivian
Fischer, Alison
Eisman, Samantha
Hu, Xiaofei
Wu, Tianshuang
Calimlim, Brian M.
Kaplan, Blair
Liu, Yingyi
Teixeira, Henrique D.
Liu, John
Eyerich, Kilian
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : 478 - 485
[40] Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial
Gaborit, Benjamin
Vanhove, Bernard
Vibet, Marie-Anne
Le Thuaut, Aurelie
Lacombe, Karine
Dubee, Vincent
Ader, Florence
Ferre, Virginie
Vicaut, Eric
Orain, Jeremie
Le Bras, Morgane
Omnes, Anne
Berly, Laetitia
Jobert, Alexandra
Morineau-Le Houssine, Pascale
Botturi, Karine
Josien, Regis
Flet, Laurent
Degauque, Nicolas
Brouard, Sophie
Duvaux, Odile
Poinas, Alexandra
Raffi, Francois
TRIALS, 2021, 22 (01)

← 1 2 3 4 5 →